The recent development of potent, clinical-grade STING agonists provides an opportunity to explore STING activation as a GBM IO.24,31,34–38 This review will discuss important developments in cGAS/STING pathway targeting, potential biomarkers indicative of cGAS/STING pathway activity, and new combinatorial therapeutic approaches for treating GBM that include agents for activating cGAS/STING. The gene discussed is STING1; the disease is glioblastoma.